GI-Innovation, a Korean biotechnology company, reported that its next-generation cytokine-based immunotherapy candidate, GI-102, demonstrated complete remission (CR) as a monotherapy in a Phase 1 clinical trial. This represents the first public disclosure of interim data from the ongoing Phase 1b clinical trial evaluating the subcutaneous (SC) formulation of GI-102. The achievement of a single complete remission (CR) with a cytokine-based agent is a rare achievement and is anticipated to serve as a catalyst for advancing technology transfer negotiations with global pharmaceutical companies.The clinical trial is being conducted at the Mayo Clinic, a globally recognized medical institution in the United States. Notably, earlier this year, the Mayo Clinic was ranked first in the World's Best Hospitals 2025 list, published by the renowned U.S. weekly magazine Newsweek with the global research organization Statista.https://www.thebionews.net/news/articleView.html?idxno=17635​

The Korean biotechnology company GI Innovation has been added to the Morgan Stanley Capital International (MSCI) Korea Index, alongside Doosan Robotics and CJ CheilJedang. MSCI announced on August 7 (local time) that, following its regular review, a total of 17 stocks have been newly included in the KOREA INDEX. The index rebalancing (adjustment of constituent stocks) is scheduled to take place after the market closes on August 26. https://www.thebionews.net/news/articleView.html?idxno=17073

GI Innovation has secured a ‘substance patent’ in the U.S., following the earlier registration of a ‘high-content sialic acid patent,’ thereby affirming the innovativeness of ‘GI-301’ (lesigercept, Yuhan Corporation development code: YH35324) in both composition and quality. GI-301 is part of the company's pipeline of next-generation allergy treatment candidates. In particular, establishing patent protection in the U.S., the world's largest pharmaceutical market, has positioned GI-301 advantageously for global technology transfer to international companies. https://www.thebionews.net/news/articleView.html?idxno=16889

GI Innovation announced on July 28 that it has secured a U.S. material patent for the protein structure combination of its next-generation allergy treatment candidate substance, ‘GI-301’ (lesigercept, Yuhan Corporation development code: YH35324). The company stated that this patent is particularly significant as it secures the rights to the main ingredient of GI-301 itself, thereby establishing an intellectual property rights system capable of providing ‘dual’ protection of GI-301, both in terms of its ingredient composition and quality, complementing that high-content sialic acid patent registered in the U.S. last May. https://www.thebionews.net/news/articleView.html?idxno=16821

GI Innovation announced on July 22 the signing of a memorandum of understanding (MOU) with Aimed Bio, a company specializing in the development of antibody-drug conjugates (ADCs), to establish a clinical research collaboration focused on glioblastoma multiforme (GBM) treatment. This MOU aims to pursue ‘Accelerated Approval’ through clinical research on combination therapy involving GI Innovation’s immunotherapy candidate, ‘GI-102 (development code),’ for patients with relapsed GBM who have undergone radiosurgery or other treatments. GI-102 has already demonstrated anticancer activity in preclinical glioblastoma models. https://www.thebionews.net/news/articleView.html?idxno=16719

GI Innovation has reported promising early clinical outcomes from the combination therapy of its immunotherapy candidate ‘GI-102 (development code)’ and MSD (Merck, USA)’s immune checkpoint inhibitor ‘Keytruda’ in patients who were refractory or resistant to prior immunotherapy. As of July 6, the objective response rate (ORR) for the ‘GI-102 + Keytruda’ combination therapy reached 75% (3 out of 4 patients), with one patient achieving complete remission (CR). https://www.thebionews.net/news/articleView.html?idxno=16243

Korean biotech company GI Innovation showcased its next-generation growth strategy at Bio USA 2025 in Boston on Tuesday. Leading the presentation was Yun Nari, head of GI Innovation's clinical strategy, who introduced the company's new drug development pipeline and global business roadmap. A licensed pharmacist, Yun joined the company’s board of directors in March and is expected to play a pivotal role in accelerating clinical decision-making, an essential function in GI Innovation’s core business of clinical-stage drug development. https://www.koreaherald.com/article/10512185?ref=naver

GI Innovation and ProGen signed a memorandum of understanding (MOU) for anti-aging research at GI Innovation's headquarters on Wednesday. Under the MOU, the two companies will begin full-scale joint research centered on three core pipelines: GI-102 (GI Innovation) to enhance immunity, GIB-7 (GI Biome) to support muscle strength and improve the intestinal environment, and PG-102 (ProGen) to improve brain cognitive function. https://www.koreabiomed.com/news/articleView.html?idxno=27644

"GI Innovation was the superstar in this IR meeting." GI Innovation and its subsidiary, GI Biome (collectively referred to as the GI Innovation Team), have recently positioned themselves as a formidable contender in the finals of the 'XPRIZE Healthspan' competition, organized by the 'XPRIZE Foundation,' bolstered by compelling clinical data. The XPRIZE Foundation is a U.S.-based non-profit organization and global competition platform dedicated to fostering pioneering scientific and technological innovations aimed at addressing critical challenges facing humanity. https://www.thebionews.net/news/articleView.html?idxno=15179

GI Innovation, a Korean biotech company, and its affiliate GI Biome said they have been named semifinalists in the XPRIZE Healthspan competition. Hosted by the U.S.-based XPRIZE ​Foundation, the global contest aims to identify groundbreaking therapeutic strategies to delay or prevent age-related diseases.Out of over 600 teams from 58 countries, the joint GI Innovation–GI Biome team was selected among the top 100 semifinalists and further recognized as one of the top 40 “Milestone 1 Winners.”This distinction includes a $250,000 prize and the opportunity to pitch before high-profile institutional investors managing multibillion-dollar funds.https://www.koreabiomed.com/news/articleView.html?idxno=27536

The global healthspan market—estimated at over $500 billion and growing—is on the cusp of a paradigm shift. At its epicenter stands GI Innovation and its sister company GI Biome, South Korean biotech pioneers whose recent semi-finalist status in the $101 million XPRIZE Healthspan competition has validated their groundbreaking anti-aging combination therapy. This milestone marks a catalyst-driven inflection point for investors seeking exposure to the next wave of longevity drugs. https://www.ainvest.com/news/fountain-youth-gi-innovation-xprize-milestone-unlocks-anti-aging-market-potential-2505/

GI Innovation, a South Korean biotech company, announced on May 13 that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company GI Biome. The XPRIZE Healthspan semi-finals ceremony is taking place in New York from May 12 to 14, with the top 40 semi-finalist teams out of more than 600 registered teams among 58 countries invited. The company has not only advanced to the semi-finals but has also been selected as one of 8 teams among the 40 semi-finalists to earn an exclusive opportunity to present its vision and innovations to high-profile, institutional global investors. https://www.investing.com/news/press-releases/gi-innovation-and-gi-biome-advance-to-the-semifinals-of-xprize-healthspan-with-antiaging-potential-of-gi102-and-gib7-combination-therapy-93CH-4040521